Subakut Sklerozan Panensefalit ve Santral Sinir Sisteminin Diğer Yavaş Virüs Enfeksiyonları
Özet
Subakut sklerozan panensefalit (SSPE), genellikle kızamık enfeksiyonundan yıllar sonra ortaya çıkan, beyin dokusunda ilerleyici nörodejeneratif hasara yol açan ölümcül bir yavaş virüs enfeksiyonudur. Hastalığın patogenezi tam olarak bilinmemekle birlikte, kızamık virüsünün beyin hücrelerinde kalıcı ve defektif bir enfeksiyon oluşturmasıyla ilişkili olduğu düşünülmektedir. Dört evrede seyreden klinik tablo, bilişsel gerileme, miyoklonus ve otonomik disfonksiyon gibi ağır nörolojik belirtilerle karakterizedir ve kesin bir tedavisi bulunmamaktadır. Tek etkili önleme yöntemi, kızamık aşısının uygun yaşlarda uygulanmasıdır.
Subacute sclerosing panencephalitis (SSPE) is a fatal, progressive neurodegenerative disease caused by a slow viral infection, typically occurring years after an initial measles infection. While the exact pathogenesis is not fully understood, it is believed to be associated with a persistent and defective measles virus infection within brain cells. Characterized by four clinical stages, the disease presents with severe neurological symptoms, including cognitive decline, myoclonus, and autonomic dysfunction, for which there is no definitive cure. The only effective method of prevention is the administration of the measles vaccine at the appropriate ages.
Referanslar
Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J. 2002; 78:63-70.
Greenfield JG. Encephalitis and encephalomyelitis in England and Wales during last decade. Brain. 1950;73:141–66.
Dawson JR. Cellular inclusions in cerebral lesions of lethargic encephalitis. Am J Pathol. 1933; 9:7–16.
Pette H, Doring G. Uber einheimische panencephalomyelitis vom charakter der encephalitis Japonica. Deutsche Zeitschrift fur Nervenheilk. 1939;149:7–44.
Van Bogaert L. Une leocoencephalite sclerosante subaigue. J Neurol Neurosurg Psychiatry. 1945;8:101–20.
Horta-Barbosa L, Fuccillo DA, Sever JL, Zeman W. Subacute sclerosing panencephalitis: Isolation of measles virus from a brain biopsy. Nature. 1969; 221: 974.
Holzmann H, Hengel H, Tenbusch M, Doerr H. Eradication of measles: remaining challenges. Med Microbiol Immunol. 2016; 205:201–208.
Garg RK. Subacute sclerosing panencephalitis. J Neurol. 2008;255: 1861–171.
Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccine. Vaccines. 2008;5:353–398.
Centers for Disease Control (CDC). Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep. 1982; 31:585.
Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis. 2005; 192:1686.
Bernstein DI, Reuman PD, Schiff GM. Rubeola (measles) and subacute sclerosing panencephalitis virus. Gorbach SL, Bartlett JG, Blacklow NR (Eds), In: Infectious Diseases, Philadelphia, WB Saunders, 1998. p. 2135.
Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clin Infect Dis. 2017; 65:226.
Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics. 1997;59:505–512.
Miller C, Farrington CP, Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970–1989. International Journal of Epidemiology. 1992; 21:998–1006.
Miller C, Andrews N, Rush M, Munro H, Jin L, Miller E. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990–2002. Arch Dis Child. 2004; 89:1145–1148.
Abe Y, Hashimoto K, Iinuma K, et al. Survey of subacute sclerosing panencephalitis in Japan. J. Child Neurol. 2012; 27:1529–1533.
Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007; 36:1334– 1348.
Cherry JD. Measles virus. 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, et al (Eds). In: Textbook of Pediatric Infectious Diseases, Philadelphia, Saunders, 2009. p.2427.
Kagame K, Schwab L. Childhood blindness: dateline Africa. Ophthalmic Surg. 1989; 20: 128.
Mason WH. Measles. Kleigman, Stanton, St Geme, Schor (eds). In: Nelson Textbook of Pediatrics.20th ed. Elsevier 2016; 1543-1548.
Santoshkumar B, Radhakrishnan K. Substantial spontaneous long-term remission in subacute sclerosing panencephalitis (SSPE). J Neurol Sci.1998; 154(1):83–88.
Saha V, Johan J, Mukundan P, et al. High incidence of subacute sclerosing panencephalitis in South India. Epidemiol Infect. 1990;104:151–6.
Dyken PR. Viral diseases of the central nervous system. In: Pediatric Neurology: Principles and Practice, Mosby, St. Louis 1994. p.670.
Fisch BJ. Periodic complexes. In: Spehlmann's EEG Primer, Fisch BJ (Ed), Elsevier Science, Amsterdam 1991. p.376.
Liko J, Guzman-Cottrill JA, Cieslak PR. Notes from the Field: Subacute Sclerosing Panencephalitis Death - Oregon, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65:10.
Prashanth LK. Taly AB, Ravi V, Sinha S, Rao S. Long term survival in subacute sclerosing panencephalitis: An enigma. Brain Dev. 2006;28:447–452.
Kartal A, Kurt AN, Gurkas E, Aydın K, Serdaroğlu A. Subacute sclerosing panencephalitis presenting as schizophrenia with an alpha coma pattern in a child. Journal of Child Neurology. 2013; 29:111-113.
Modlin JF, Halsey NA, Eddins DL, et al. Epidemiology of subacute sclerosing panencephalitis. J Pediatr. 1979;94:231–6.
Singer C, Lang AE, Suchowersky O. Adult-onset subacute sclerosing panencephalitis: case reports and review of literature. Mov Disord. 1997;10:342–53.
Risk WS. Haddad FS. The variable natural history of subacute sclerosing panencephalitis: A study of 118 cases from the Middle East. Arch Neurol. 1979; 36, 610–614.
Anlar B, Saatçi I, Köse G, Yalaz K. MRI findings in subacute sclerosing panencephalitis. Neurology. 1996; 47 (5).
Seo YS, Kim HS, Jung DE. 18F-FDG PET and MRS of the early stages of subacute sclerosing panencephalitis in a child with a normal initial MRI. Pediatr Radiol. 2010; 40:1822.
Cece H, Tokay L, Yildiz S, Karakas O, Karakas E, Iscan A. Epidemiological findings and clinical and magnetic resonance presentations in subacute sclerosing panencephalitis. J Int Med Res. 2011; 39, 594–602.
Alkan A, Korkmaz, L, Sigirci A et al. Subacute sclerosing panencephalitis: Relationship between clinical stage and diffusion-weighted imaging findings. J Magn Reson Imaging. 2006; 23, 267–272.
Dyken PR. Subacute sclerosing panencephalitis. Neurol Clin. 1985;3:179–95.
Griffin DE, Bellini WJ. Measles virus. Fields BN, Knipe DM, Howley PM (Eds), In: Fields' Virology. Philadelphia Lippincott-Raven, 1996; p.1267.
Saini AG, Sankhyan N, Padmanabh H. Sahu JK, Vyas S, Singhi P. Subacute sclerosing panencephalitis presenting as acute cerebellar ataxia and brain stem hyperintensities. Eur J Paediatr Neurol. 2016; 20:435–438.
Gascon G. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): International multicenter study. Journal of Child Neurology. 2003; 18:819–827.
Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: An update. Developmental Medicine and Child Neurology. 2010; 52:901–907.
Beckham JD, Solbrig MV, Tyler KJ. Viral Encephalitis and Meningitis.Neurological Disease and Their Treatment, Book Chapter 78, 1184-1213.
Gascon GG, Anlar B, Güven A, et al. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-a in subacute sclerosing panencephalitis (SSPE): international multicenter study, J. Child Neurol. 2003; 18.
Hashimoto K, Hosoya M. Advances in antiviral therapy for subacute sclerosing panencephalitis, Molecules 2021;26:427.
SSPE Hastalığı. T.C Sağlık Bakanlığı Aşı Portalı. Erişim: https://asi.saglik.gov.tr/liste/38-44. sspe-hastaligi-subakut-sklerozan-panensefalit.htm
